 Rockwell Medical Incs NASDAQ: RMTI partner, Jeil Pharmaceutical Co Ltd, has received regulatory approval in South Korea for Triferic Injection for iron supplementation therapy and maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Rockwell Medical has an exclusive license agreement with Jeil to commercialize Triferic in South Korea. 